共 181 条
[111]
McMillan SA(2015)CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin Mol Cancer Ther 14 1376-244
[112]
Barbieri A(2014)Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline J Clin Oncol 32 1941-143
[113]
Shinoda K(2012)Brentuximab associated progressive multifocal leukoencephalopathy Clin Neurol Neurosurg 114 1335-297
[114]
Gerli R(2014)Acute pancreatitis following brentuximab vedotin therapy for refractory Hodgkin lymphoma: a case report Drugs R D 14 9-1107
[115]
Younes A(2014)Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a report of 5 cases from the Southern Network on Adverse Reactions (SONAR) project Cancer 120 2464-327
[116]
Younes A(2014)Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event Blood 123 2895-4475
[117]
Chen R(2017)Safety and efficacy of combination of brentuximab vedotin and Nivolumab in relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Cancer research group (E4412) Hematol Oncol 128 1106-1814
[118]
Pro B(2018)Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma Blood 131 1183-2093
[119]
Moskowitz CH(1995)A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP Science 269 242-1845
[120]
Younes A(2009)CD22 and Siglec-G: B-cell inhibitory receptors with distinct functions Immunol Rev 230 128-581